2019 ARIA Care pathways for allergen immunotherapy

Simple item page
dc.contributor.authorBousquet J.
dc.contributor.authorPfaar O.
dc.contributor.authorTogias A.
dc.contributor.authorSchünemann H.J.
dc.contributor.authorAnsotegui I.
dc.contributor.authorPapadopoulos N.G.
dc.contributor.authorTsiligianni I.
dc.contributor.authorAgache I.
dc.contributor.authorAnto J.M.
dc.contributor.authorBachert C.
dc.contributor.authorBedbrook A.
dc.contributor.authorBergmann K.-C.
dc.contributor.authorBosnic-Anticevich S.
dc.contributor.authorBosse I.
dc.contributor.authorBrozek J.
dc.contributor.authorCalderon M.A.
dc.contributor.authorCanonica G.W.
dc.contributor.authorCaraballo L.
dc.contributor.authorCardona V.
dc.contributor.authorCasale T.
dc.contributor.authorCecchi L.
dc.contributor.authorChu D.
dc.contributor.authorCosta E.
dc.contributor.authorCruz A.A.
dc.contributor.authorCzarlewski W.
dc.contributor.authorDurham S.R.
dc.contributor.authorDu Toit G.
dc.contributor.authorDykewicz M.
dc.contributor.authorEbisawa M.
dc.contributor.authorFauquert J.L.
dc.contributor.authorFernandez-Rivas M.
dc.contributor.authorFokkens W.J.
dc.contributor.authorFonseca J.
dc.contributor.authorFontaine J.-F.
dc.contributor.authorGerth van Wijk R.
dc.contributor.authorHaahtela T.
dc.contributor.authorHalken S.
dc.contributor.authorHellings P.W.
dc.contributor.authorIerodiakonou D.
dc.contributor.authorIinuma T.
dc.contributor.authorIvancevich J.C.
dc.contributor.authorJacobsen L.
dc.contributor.authorJutel M.
dc.contributor.authorKaidashev I.
dc.contributor.authorKhaitov M.
dc.contributor.authorKalayci O.
dc.contributor.authorKleine Tebbe J.
dc.contributor.authorKlimek L.
dc.contributor.authorKowalski M.L.
dc.contributor.authorKuna P.
dc.contributor.authorKvedariene V.
dc.contributor.authorLa Grutta S.
dc.contributor.authorLarenas-Linemann D.
dc.contributor.authorLau S.
dc.contributor.authorLaune D.
dc.contributor.authorLe L.
dc.contributor.authorLodrup Carlsen K.
dc.contributor.authorLourenço O.
dc.contributor.authorMalling H.-J.
dc.contributor.authorMarien G.
dc.contributor.authorMenditto E.
dc.contributor.authorMercier G.
dc.contributor.authorMullol J.
dc.contributor.authorMuraro A.
dc.contributor.authorO’Hehir R.
dc.contributor.authorOkamoto Y.
dc.contributor.authorPajno G.B.
dc.contributor.authorPark H.-S.
dc.contributor.authorPanzner P.
dc.contributor.authorPassalacqua G.
dc.contributor.authorPham-Thi N.
dc.contributor.authorRoberts G.
dc.contributor.authorPawankar R.
dc.contributor.authorRolland C.
dc.contributor.authorRosario N.
dc.contributor.authorRyan D.
dc.contributor.authorSamolinski B.
dc.contributor.authorSanchez-Borges M.
dc.contributor.authorScadding G.
dc.contributor.authorShamji M.H.
dc.contributor.authorSheikh A.
dc.contributor.authorSturm G.J.
dc.contributor.authorTodo Bom A.
dc.contributor.authorToppila-Salmi S.
dc.contributor.authorValentin-Rostan M.
dc.contributor.authorValiulis A.
dc.contributor.authorValovirta E.
dc.contributor.authorVentura M.-T.
dc.contributor.authorWahn U.
dc.contributor.authorWalker S.
dc.contributor.authorWallace D.
dc.contributor.authorWaserman S.
dc.contributor.authorYorgancioglu A.
dc.contributor.authorZuberbier T.
dc.date.accessioned2024-07-22T08:08:12Z
dc.date.available2024-07-22T08:08:12Z
dc.date.issued2019
dc.description.abstractAllergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
dc.identifier.DOI-ID10.1111/all.13805
dc.identifier.issn01054538
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14290
dc.language.isoEnglish
dc.publisherBlackwell Publishing Ltd
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAllergens
dc.subjectAnimals
dc.subjectAsthma
dc.subjectAttitude of Health Personnel
dc.subjectBiomarkers
dc.subjectClinical Decision-Making
dc.subjectComorbidity
dc.subjectCost of Illness
dc.subjectCost-Benefit Analysis
dc.subjectCritical Pathways
dc.subjectDesensitization, Immunologic
dc.subjectDisease Management
dc.subjectDisease Susceptibility
dc.subjectHumans
dc.subjectPractice Guidelines as Topic
dc.subjectPrecision Medicine
dc.subjectRhinitis, Allergic
dc.subjectTreatment Outcome
dc.subjectallergen
dc.subjectbiological marker
dc.subjectallergen
dc.subjectbiological marker
dc.subjectallergic disease
dc.subjectallergic rhinitis
dc.subjectasthma
dc.subjectclinical pathway
dc.subjectcost effectiveness analysis
dc.subjectdesensitization
dc.subjectdisease exacerbation
dc.subjectfollow up
dc.subjecthealth care personnel
dc.subjecthuman
dc.subjectimmunotherapy
dc.subjectmultiple chronic conditions
dc.subjectnonhuman
dc.subjectpatient attitude
dc.subjectpharmacist attitude
dc.subjectpriority journal
dc.subjectReview
dc.subjectrhinitis
dc.subjectrhinoconjunctivitis
dc.subjectsubcutaneous immunotherapy
dc.subjectsublingual immunotherapy
dc.subjectadverse event
dc.subjectallergic rhinitis
dc.subjectanimal
dc.subjectasthma
dc.subjectclinical decision making
dc.subjectcomorbidity
dc.subjectcost benefit analysis
dc.subjectcost of illness
dc.subjectdisease management
dc.subjectdisease predisposition
dc.subjecthealth personnel attitude
dc.subjectimmunology
dc.subjectpersonalized medicine
dc.subjectpractice guideline
dc.subjectprocedures
dc.subjecttreatment outcome
dc.title2019 ARIA Care pathways for allergen immunotherapy
dc.typeReview

Files

Collections

Scopus Koleksiyonu